-
Something wrong with this record ?
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial
S. Kreissl, H. Goergen, I. Buehnen, C. Kobe, A. Moccia, R. Greil, DA. Eichenauer, JM. Zijlstra, J. Markova, J. Meissner, M. Feuring-Buske, M. Soekler, HJ. Beck, W. Willenbacher, WD. Ludwig, T. Pabst, MS. Topp, F. Hitz, M. Bentz, UB. Keller, D....
Language English Country Great Britain
Document type Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial
- MeSH
- Bleomycin administration & dosage MeSH
- Progression-Free Survival MeSH
- Adult MeSH
- Doxorubicin administration & dosage MeSH
- Etoposide administration & dosage MeSH
- Hodgkin Disease drug therapy mortality pathology MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Follow-Up Studies MeSH
- Positron-Emission Tomography MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Rituximab administration & dosage MeSH
- Neoplasm Staging MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial, Phase III MeSH
- Multicenter Study MeSH
- Randomized Controlled Trial MeSH
BACKGROUND: The German Hodgkin Study Group's HD18 trial established the safety and efficacy of PET-guided eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses) for the treatment of advanced-stage Hodgkin lymphoma. However, because of a protocol amendment during the enrolment period (June 1, 2011) that changed standard treatment from eight to six cycles, the results of the HD18 trial have been partially immature. We report a prespecified 5-year follow-up analysis of the completed HD18 trial. METHODS: HD18 was an international, open-label, randomised, phase 3 trial done in 301 hospitals and private practices in five European countries. Patients aged 18-60 years with newly diagnosed, advanced-stage Hodgkin lymphoma and an Eastern Cooperative Oncology Group performance status of 0-2 were recruited. After receiving an initial two cycles of eBEACOPP (1250 mg/m2 intravenous cyclophosphamide [day 1], 35 mg/m2 intravenous doxorubicin [day 1], 200 mg/m2 intravenous etoposide [day 1-3], 100 mg/m2 oral procarbazine [day 1-7], 40 mg/m2 oral prednisone [day 1-14], 1·4 mg/m2 intravenous vincristine [day 8], and 10 mg/m2 intravenous bleomycin [day 8]), patients underwent a contrast-enhanced CT and PET scan (PET-2). Patients with positive PET-2 were randomly assigned to receive standard therapy (an additional six cycles of eBEACOPP; ie, eight cycles in total) or experimental therapy (an additional six cycles of eBEACOPP plus 375 mg/m2 intravenous rituximab; ie, eight cycles in total) until June 1, 2011. After June 1, 2011, all patients with positive PET-2 were assigned to the updated standard therapy with an additional four cycles of eBEACOPP (ie, six cycles in total). Patients with negative PET-2 were randomly assigned (1:1) to receive standard therapy (an additional six cycles of eBEACOPP [ie, eight cycles in total] until June 1, 2011; an additional four cycles of eBEACOPP [ie, six cycles in total] after June 1, 2011) or experimental therapy (an additional two cycles of eBEACOPP; ie, four cycles in total). Randomisation was done centrally with the minimisation method, including a random component, stratified by centre, age, stage, international prognostic score, and sex. The primary endpoint was progression-free survival. HD18 aimed to improve 5-year progression-free survival by 15% in the PET-2-positive intention-to-treat cohort and to exclude inferiority of 6% or more in 5-year progression-free survival in the PET-2-negative per-protocol population. This study is registered with ClinicalTrials.gov, NCT00515554, and is completed. FINDINGS: Between May 14, 2008, and July 18, 2014, 2101 patients were enrolled and 1945 were assigned to a treatment group according to their PET-2 result. In the PET-2-positive cohort, with a median follow-up of 73 months (IQR 59 to 94), 5-year progression-free survival was 89·9% (95% CI 85·7 to 94·1) in 217 patients assigned to eight cycles of eBEACOPP before the protocol amendment and 87·7% (83·1 to 92·4) in 217 patients assigned to eight cycles of rituximab plus eBEACOPP (p=0·40). Among 506 patients who received six cycles of eBEACOPP after the protocol amendment, 5-year progression-free survival was 90·1% (95% CI 87·2 to 92·9), with a median follow-up of 58 months (IQR 39 to 66). In the PET-2-negative cohort, with a median follow-up of 66 months (IQR 54 to 85) in the combined pre-amendment and post-amendment groups, 5-year progression-free survival was 91·2% (95% CI 88·4 to 93·9) in 446 patients who received eight or six cycles of eBEACOPP and 93·0% (90·6 to 95·4) in 474 patients who received four cycles of eBEACOPP (difference 1·9% [95% CI -1·8 to 5·5]). In the subgroup of PET-2-negative patients randomly assigned after protocol amendment, 5-year progression-free survival was 90·9% (95% CI 86·8 to 95·1) in 202 patients assigned to receive six cycles of eBEACOPP and 91·0% (86·6 to 95·5) in 200 patients assigned to receive four cycles of eBEACOPP (difference 0·1% [-5·9 to 6·2]). INTERPRETATION: Long-term follow-up confirms the efficacy and safety of PET-2-guided eBEACOPP in patients with advanced-stage Hodgkin lymphoma. The reduction from eight to four cycles of eBEACOPP represents a benchmark in the treatment of early-responding patients, who can now be potentially cured with a short and safe treatment approach. FUNDING: Deutsche Krebshilfe, Swiss State Secretariat for Education, Research and Innovation SERI (Switzerland), and Roche Pharma. TRANSLATION: For the German translation of the abstract see Supplementary Materials section.
Berlin Reference Center for Lymphoma and Haematopathology Berlin Germany
Cantonal Hospital of St Gallen St Gallen Switzerland
Department of Haematology and Oncology Robert Bosch Hospital Stuttgart Germany
Department of Haematology Oncology and Palliative Care Ernst von Bergmann Hospital Potsdam Germany
Department of Hematology and Oncology Charité University of Medicine Berlin Germany
Department of Hematology Oncology University Hospital of Munich Munich Germany
Department of Internal Medicine 1 Klinikum Bremen Mitte Bremen Germany
Department of Internal Medicine 3 Städtisches Klinikum Karlsruhe Karlsruhe Germany
Department of Internal Medicine 3 University Hospital of Ulm Ulm Germany
Department of Medical Oncology Inselspital Bern Bern Switzerland
Department of Medical Oncology Oncology Institute of Southern Switzerland Bellinzona Switzerland
Department of Nuclear Medicine University Hospital of Cologne University of Cologne Cologne Germany
Department of Radiotherapy University Hospital of Cologne University of Cologne Cologne Germany
Department of Radiotherapy University Hospital of Münster Münster Germany
HELIOS Medical Center Berlin Buch Berlin Germany
Karl Lennert Cancer Center University Hospital Schleswig Holstein Kiel Germany
Medical Department Division of Hematology and Oncology at Campus Benjamin Franklin Berlin Germany
Medical University Innsbruck Internal Medicine 5 Hematology and Oncology Innsbruck Austria
Medizinische Klinik und Poliklinik 2 Universitätsklinikum Würzburg Würzburg Germany
Oncotyrol Center for Personalized Cancer Medicine Innsbruck Austria
Swiss Group for Clinical Cancer Research Bern Switzerland
University Hospital Mainz Mainz Germany
University of Heidelberg Heidelberg Germany
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21018526
- 003
- CZ-PrNML
- 005
- 20210830100121.0
- 007
- ta
- 008
- 210728s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S2352-3026(21)00101-0 $2 doi
- 035 __
- $a (PubMed)34048679
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Kreissl, Stefanie $u German Hodgkin Study Group, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German Hodgkin Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany
- 245 10
- $a PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial / $c S. Kreissl, H. Goergen, I. Buehnen, C. Kobe, A. Moccia, R. Greil, DA. Eichenauer, JM. Zijlstra, J. Markova, J. Meissner, M. Feuring-Buske, M. Soekler, HJ. Beck, W. Willenbacher, WD. Ludwig, T. Pabst, MS. Topp, F. Hitz, M. Bentz, UB. Keller, D. Kühnhardt, H. Ostermann, B. Hertenstein, W. Aulitzky, G. Maschmeyer, T. Vieler, H. Eich, C. Baues, H. Stein, M. Fuchs, V. Diehl, M. Dietlein, A. Engert, P. Borchmann, German Hodgkin Study Group
- 520 9_
- $a BACKGROUND: The German Hodgkin Study Group's HD18 trial established the safety and efficacy of PET-guided eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses) for the treatment of advanced-stage Hodgkin lymphoma. However, because of a protocol amendment during the enrolment period (June 1, 2011) that changed standard treatment from eight to six cycles, the results of the HD18 trial have been partially immature. We report a prespecified 5-year follow-up analysis of the completed HD18 trial. METHODS: HD18 was an international, open-label, randomised, phase 3 trial done in 301 hospitals and private practices in five European countries. Patients aged 18-60 years with newly diagnosed, advanced-stage Hodgkin lymphoma and an Eastern Cooperative Oncology Group performance status of 0-2 were recruited. After receiving an initial two cycles of eBEACOPP (1250 mg/m2 intravenous cyclophosphamide [day 1], 35 mg/m2 intravenous doxorubicin [day 1], 200 mg/m2 intravenous etoposide [day 1-3], 100 mg/m2 oral procarbazine [day 1-7], 40 mg/m2 oral prednisone [day 1-14], 1·4 mg/m2 intravenous vincristine [day 8], and 10 mg/m2 intravenous bleomycin [day 8]), patients underwent a contrast-enhanced CT and PET scan (PET-2). Patients with positive PET-2 were randomly assigned to receive standard therapy (an additional six cycles of eBEACOPP; ie, eight cycles in total) or experimental therapy (an additional six cycles of eBEACOPP plus 375 mg/m2 intravenous rituximab; ie, eight cycles in total) until June 1, 2011. After June 1, 2011, all patients with positive PET-2 were assigned to the updated standard therapy with an additional four cycles of eBEACOPP (ie, six cycles in total). Patients with negative PET-2 were randomly assigned (1:1) to receive standard therapy (an additional six cycles of eBEACOPP [ie, eight cycles in total] until June 1, 2011; an additional four cycles of eBEACOPP [ie, six cycles in total] after June 1, 2011) or experimental therapy (an additional two cycles of eBEACOPP; ie, four cycles in total). Randomisation was done centrally with the minimisation method, including a random component, stratified by centre, age, stage, international prognostic score, and sex. The primary endpoint was progression-free survival. HD18 aimed to improve 5-year progression-free survival by 15% in the PET-2-positive intention-to-treat cohort and to exclude inferiority of 6% or more in 5-year progression-free survival in the PET-2-negative per-protocol population. This study is registered with ClinicalTrials.gov, NCT00515554, and is completed. FINDINGS: Between May 14, 2008, and July 18, 2014, 2101 patients were enrolled and 1945 were assigned to a treatment group according to their PET-2 result. In the PET-2-positive cohort, with a median follow-up of 73 months (IQR 59 to 94), 5-year progression-free survival was 89·9% (95% CI 85·7 to 94·1) in 217 patients assigned to eight cycles of eBEACOPP before the protocol amendment and 87·7% (83·1 to 92·4) in 217 patients assigned to eight cycles of rituximab plus eBEACOPP (p=0·40). Among 506 patients who received six cycles of eBEACOPP after the protocol amendment, 5-year progression-free survival was 90·1% (95% CI 87·2 to 92·9), with a median follow-up of 58 months (IQR 39 to 66). In the PET-2-negative cohort, with a median follow-up of 66 months (IQR 54 to 85) in the combined pre-amendment and post-amendment groups, 5-year progression-free survival was 91·2% (95% CI 88·4 to 93·9) in 446 patients who received eight or six cycles of eBEACOPP and 93·0% (90·6 to 95·4) in 474 patients who received four cycles of eBEACOPP (difference 1·9% [95% CI -1·8 to 5·5]). In the subgroup of PET-2-negative patients randomly assigned after protocol amendment, 5-year progression-free survival was 90·9% (95% CI 86·8 to 95·1) in 202 patients assigned to receive six cycles of eBEACOPP and 91·0% (86·6 to 95·5) in 200 patients assigned to receive four cycles of eBEACOPP (difference 0·1% [-5·9 to 6·2]). INTERPRETATION: Long-term follow-up confirms the efficacy and safety of PET-2-guided eBEACOPP in patients with advanced-stage Hodgkin lymphoma. The reduction from eight to four cycles of eBEACOPP represents a benchmark in the treatment of early-responding patients, who can now be potentially cured with a short and safe treatment approach. FUNDING: Deutsche Krebshilfe, Swiss State Secretariat for Education, Research and Innovation SERI (Switzerland), and Roche Pharma. TRANSLATION: For the German translation of the abstract see Supplementary Materials section.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a bleomycin $x aplikace a dávkování $7 D001761
- 650 _2
- $a doxorubicin $x aplikace a dávkování $7 D004317
- 650 _2
- $a etoposid $x aplikace a dávkování $7 D005047
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a Hodgkinova nemoc $x farmakoterapie $x mortalita $x patologie $7 D006689
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a pozitronová emisní tomografie $7 D049268
- 650 _2
- $a doba přežití bez progrese choroby $7 D000077982
- 650 _2
- $a rituximab $x aplikace a dávkování $7 D000069283
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Goergen, Helen $u German Hodgkin Study Group, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German Hodgkin Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany
- 700 1_
- $a Buehnen, Ina $u German Hodgkin Study Group, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German Hodgkin Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany
- 700 1_
- $a Kobe, Carsten $u Department of Nuclear Medicine, University Hospital of Cologne, University of Cologne, Cologne, Germany
- 700 1_
- $a Moccia, Alden $u Department of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
- 700 1_
- $a Greil, Richard $u IIIrd Medical Department, Paracelsus Medical University and Salzburg Cancer Research Institute, Salzburg, Austria; Salzburg Cancer Research Institute and Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria
- 700 1_
- $a Eichenauer, Dennis A $u German Hodgkin Study Group, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German Hodgkin Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany
- 700 1_
- $a Zijlstra, Josée M $u VU University Medical Center, Amsterdam, Netherlands
- 700 1_
- $a Markova, Jana $u Department of Internal Medicine - Hematology, University Hospital Kralovske Vinohrady, Third Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Meissner, Julia $u University of Heidelberg, Heidelberg, Germany
- 700 1_
- $a Feuring-Buske, Michaela $u Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
- 700 1_
- $a Soekler, Martin $u University of Tübingen, Tübingen, Germany
- 700 1_
- $a Beck, Hans-Joachim $u University Hospital Mainz, Mainz, Germany
- 700 1_
- $a Willenbacher, Wolfgang $u Salzburg Cancer Research Institute and Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; Medical University Innsbruck, Internal Medicine V: Hematology & Oncology, Innsbruck, Austria; Oncotyrol, Center for Personalized Cancer Medicine, Innsbruck, Austria
- 700 1_
- $a Ludwig, Wolf-Dieter $u HELIOS Medical Center Berlin-Buch, Berlin, Germany
- 700 1_
- $a Pabst, Thomas $u Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Department of Medical Oncology, Inselspital Bern, Bern, Switzerland
- 700 1_
- $a Topp, Max S $u Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany
- 700 1_
- $a Hitz, Felicitas $u Cantonal Hospital of St Gallen, St Gallen, Switzerland
- 700 1_
- $a Bentz, Martin $u Department of Internal Medicine III, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany
- 700 1_
- $a Keller, Ulrich Bernd $u Medical Department, Division of Hematology and Oncology at Campus Benjamin Franklin, Berlin, Germany
- 700 1_
- $a Kühnhardt, Dagmar $u Department of Hematology and Oncology, Charité University of Medicine, Berlin, Germany
- 700 1_
- $a Ostermann, Helmut $u Department of Hematology/Oncology, University Hospital of Munich, Munich, Germany
- 700 1_
- $a Hertenstein, Bernd $u Department of Internal Medicine I, Klinikum Bremen Mitte, Bremen, Germany
- 700 1_
- $a Aulitzky, Walter $u Department of Haematology and Oncology, Robert Bosch Hospital, Stuttgart, Germany
- 700 1_
- $a Maschmeyer, Georg $u Department of Haematology, Oncology and Palliative Care, Ernst von Bergmann Hospital, Potsdam, Germany
- 700 1_
- $a Vieler, Tom $u Karl Lennert-Cancer Center, University Hospital Schleswig-Holstein, Kiel, Germany
- 700 1_
- $a Eich, Hans $u Department of Radiotherapy, University Hospital of Münster, Münster, Germany
- 700 1_
- $a Baues, Christian $u Department of Radiotherapy, University Hospital of Cologne, University of Cologne, Cologne, Germany
- 700 1_
- $a Stein, Harald $u Berlin Reference Center for Lymphoma and Haematopathology, Berlin, Germany
- 700 1_
- $a Fuchs, Michael $u German Hodgkin Study Group, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German Hodgkin Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany
- 700 1_
- $a Diehl, Volker $u German Hodgkin Study Group, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German Hodgkin Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany
- 700 1_
- $a Dietlein, Markus $u Department of Nuclear Medicine, University Hospital of Cologne, University of Cologne, Cologne, Germany
- 700 1_
- $a Engert, Andreas $u German Hodgkin Study Group, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German Hodgkin Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany
- 700 1_
- $a Borchmann, Peter $u German Hodgkin Study Group, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German Hodgkin Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany. Electronic address: peter.borchmann@uk-koeln.de
- 710 2_
- $a German Hodgkin Study Group
- 773 0_
- $w MED00193479 $t The Lancet. Haematology $x 2352-3026 $g Roč. 8, č. 6 (2021), s. e398-e409
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34048679 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830100121 $b ABA008
- 999 __
- $a ok $b bmc $g 1689581 $s 1138972
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 8 $c 6 $d e398-e409 $e - $i 2352-3026 $m The Lancet. Haematology $n Lancet Haematol $x MED00193479
- LZP __
- $a Pubmed-20210728
